Skip to content

Using electronic nose measurements to capture subgroups of children with asthma.

Using electronic nose measurements to capture subgroups of children with asthma.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON25508
Enrollment
75
Registered
2012-04-25
Start date
2012-05-02
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma control in children

Interventions

This will be a cross-sectional study. Data will be collected once per patient in a period of 6 months, in the same occasion as their routine visit in the outpatient clinics. Asthma control will be eva

Sponsors

Academic Medical Centre University of Amsterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Males and females aged 6 to 17 years (inclusive); 2. Parent/ guardian must be able to give written informed consent prior to participation in the study, which includes ability to comply with the requirements and restrictions listed in the consent form. Informed consent must be obtained prior to undertaking any study procedures; 3. Assent should be obtained from all children in the study where appropriate; 4. For children in the asthma groups, the diagnosis of asthma should be given by specialists according to the GINA guidelines; 5. For the control-group children should have no known respiratory or other systemic diseases.

Exclusion criteria

Exclusion criteria: 1. Known underlying respiratory tract disease like congenital airway abnormalities, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia or bronchiectasis; 2. Known systemic or inflammatory diseases; 3. History or current evidence of an upper or lower respiratory infection or symptoms (including common cold) within 2 weeks of baseline assessment (assessment should be deferred); 4. The child has had a exacerbation (requiring ER attendance or hospital admission and /or a course of high dose OCS for at least 3 days duration) within 4 weeks of the baseline assessment (assessment should be deferred).

Design outcomes

Primary

MeasureTime frame
1. Asthma control score; 2. VOC’s of breath prints in exhaled air by gas chromatography mass spectrometry (GC-MS) and electronic nose (eNose).

Secondary

MeasureTime frame
1. Fractional exhaled Nitric Oxide; 2. FEV1, PEF.

Contacts

Public ContactPeter J. Sterk

Dept. Pulmonology, F5-259 Academic Medical Center University of Amsterdam P.O. Box 22700

p.j.sterk@amc.nl+31 (0)20 5668137 or +31 (0)20 5664356

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)